New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Merck & Co., Inc.

MRK

Healthcare Drug Manufacturers General

Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024.

Revenue
+4.68%
EPS
−12.1%
Free cash flow
−19.3%
Total debt
+24.3%

Quarter to September 2026, against a year earlier

134.93 2.19 +1.65%
Market cap
$328.6B
P/E
137×
Fwd P/E FY26e
105×
Dividend yield
2.56%
F-score
4/9
ROIC
4.56%
Net debt / EBITDA
1.2×
Payout ratio
3.5×

Merck & Co., Inc. (MRK) EV/FCF

Alert me on EV/FCF

As of Nov 19, 2026, Merck & Co., Inc. (MRK) trades at a EV/FCF of 24.9×. Over the past ten years it has ranged from 12.3× (May 2025) to 538× (December 2020); the current reading is higher than 47% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 23.9× 58.70%
FY2024 15.1× (56.11%)
FY2023 34.3× 70.02%
FY2022 20.2× (19.10%)
FY2021 25.0× (63.34%)
FY2020 68.1× 58.14%
FY2019 43.0× 72.44%
FY2018 25.0× (29.24%)
FY2017 35.3× 81.31%
FY2016 19.5× 43.77%

Quarterly newest first

Period EV/FCF Change
Sep 2026 27.0× 20.18%
Jun 2026 22.5× (6.15%)
Mar 2026 24.0× 0.24%
Dec 2025 23.9× 34.98%
43 more quarters

Against its own ten years

Low 12.3× High 538×
Ten-year median 25.3×
Current reading's percentile 47

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on MRK